The Structural Basis for Arenavirus Neutralization and Receptor Binding

$293,744U54FY2008AINIH

University Of California-Irvine, Irvine CA

Investigators

Linked publications & trials

Paper 39700310 Paper 37770825 Paper 35385558 Paper 34232731 Paper 33875673 Paper 33772012 Paper 32028234 Paper 31710650 Paper 31439817 Paper 31355335 Paper 30733412 Paper 30429254 Paper 30266790 Paper 30010906 Paper 29912689 Paper 29740542 Paper 29375803 Paper 29253888 Paper 29056727 Paper 28910637 Paper 28878005 Paper 28811681 Paper 28381638 Paper 28150014 Paper 27994103 Paper 27821741 Paper 27637937 Paper 27622505 Paper 27578819 Paper 27548738 Paper 27502570 Paper 27453220 Paper 27421645 Paper 27381345 Paper 27214236 Paper 27203423 Paper 27184629 Paper 27110809 Paper 27098957 Paper 27096636 Paper 27011353 Paper 27010636 Paper 26991052 Paper 26981874 Paper 26915013 Paper 26845332 Paper 26781134 Paper 26643533 Paper 26633496 Paper 26569594 Paper 26559321 Paper 26428458 Paper 26355030 Paper 26334914 Paper 26283330 Paper 26198038 Paper 26138979 Paper 26111519 Paper 26075364 Paper 26042386 Paper 26041296 Paper 26024881 Paper 26005106 Paper 26004185 Paper 25993603 Paper 25978311 Paper 25938510 Paper 25937339 Paper 25922393 Paper 25900925 Paper 25892972 Paper 25849636 Paper 25825759 Paper 25803742 Paper 25786241 Paper 25782006 Paper 25734151 Paper 25723168 Paper 25721127 Paper 25710914 Paper 25694144 Paper 25547414 Paper 25521812 Paper 25423131 Paper 25405640 Paper 25392218 Paper 25388117 Paper 25362065 Paper 25352624 Paper 25312349 Paper 25239905 Paper 25231992 Paper 25205464 Paper 25205093 Paper 25157120 Paper 25112421 Paper 25108381 Paper 25024392 Paper 24928618 Paper 24871603

Abstract

Abstract These studies propose a detailed investigation of the structural and functional consequences of arenavirus neutralizing antibody binding. The analysis of monoclonal antibodies developed for arenaviruses has shown that neutralizing epitopes localize to the viral glycoprotein (GP-C), particularly to the receptor-binding GP-1 subunit (8). Earlier studies have defined epitope regions on GP-C, and identified several cross-reactive antibodies. Binding sites of LCMV antibodies will be used as a paradigm to define GP-1 neutralizing epitopes across the arenaviridae. Novel antibodies could have therapeutic, diagnostic, or disease response potential, since protective vertical or humoral transfer of passive immunity has been reported in animal models of arenavirus infection. Junin virus, the agent of Argentinean Hemorrhagic fever, has also been shown to be amenable to treatment by intervention with human convalescent sera. Neutralizing antibody epitopes will be mapped to sequences and the low-resolution 3D cryo-EM structure of GP-C. Effects of neutralizing antibody binding on viral attachment, fusion and infectivity will be investigated separately. These results will be applied to the design of new antibodies with the highest probability of neutralizing activity for Junin virus, based on the high percentage of amino acid conservation among arenaviruses. Antibodies will be produced, targeted to regions of the Junin virus and vaccine strain Candid 1 GP-C that are homologous to regions containing LCMV neutralizing epitopes. The neutralizing potential of these antibodies will be compared to known and novel Junin antisera and serum from vaccinated or convalescent Junin patients to determine how GP-C epitopes and functions are targeted in a protective humoral response. The overall aim is to develop a rational structure-based means of designing neutralizing antibodies to any known or emerging arenavirus.

View original record on NIH RePORTER →